Kyowa Kirin Co. (TYO: 4151), a Japanese pharmaceutical firm, has secured marketing approval from China’s National Medical Products Administration (NMPA) for its novel drug evocalcet. The drug is indicated for the treatment of secondary hyperparathyroidism (SHPT) in patients undergoing maintenance dialysis due to chronic kidney disease (CKD).
Evocalcet, classified as a next-generation calcimimetic agent, operates by inhibiting the proliferation of parathyroid cells and the secretion of parathyroid hormone (PTH). It achieves this by modulating calcium-sensitive receptors on parathyroid cells. In China, SHPT affects approximately 60% of patients on dialysis, with a compliance rate in PTH control at a mere 55%. Current treatment paradigms for SHPT encompass nutritional therapy, nutritional vitamin D, active vitamin D and its analogues, as well as calcium mimetics and phosphorus binders.- Flcube.com
